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Abstract 
Alzheimer’s disease (AD) is a neurodegenerative disorder characterised by brain accumulation of 
toxic protein aggregates, including extracellular amyloid beta (Aβ) plaques, inflammation, neuronal 
death and progressive cognitive dysfunction. Current diagnostic modalities, based on cognitive tests, 
fail to detect early AD onset, thus emphasising the need to develop improved methods for 
pre-symptomatic disease detection.  
Building on the properties of the Pittsburgh Compound B (PiB), an Aβ-binding molecule suitable to 
use as positron emission tomography (PET) imaging agent, and aiming at using a more clinically 
available modality (like magnetic ressonance imaging, MRI), PiB derivatives have been conjugated to 
the macrocyclic chelator 1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane (DO3A) 
monoamide. However, these derivatives do not readily cross the highly selective blood-brain 
barrier (BBB). Taking advantage of the capacity of functionalised carbon nanotubes (f-CNTs) to 
cross biological barriers, including the BBB, this manuscript reports on the conjugation of two PiB 
derivative Gd3+ complexes – Gd(L2) and Gd(L3) – to multi-walled f-CNTs (f-MWNTs) and 
assessment of their in vivo biodistribution and brain uptake. It is shown that Gd(L2) and Gd(L3) can be 
efficiently loaded onto different f-MWNTs, with significant improvement in brain accumulation of 
the conjugates compared to the free metal complexes.  
Overall, this study demonstrates that f-MWNTs have potential to be used as carriers in theranostic 
applications involving brain delivery of BBB impermeable compounds. 
Key words: Alzheimer’s disease, Aβ plaques, Pittsburgh Compound B, carbon nanotubes (CNTs), brain delivery 
Introduction 
Alzheimer’s disease (AD) is a chronic 
neurodegenerative disorder affecting mostly the 
elderly population, characterised by brain 
accumulation of protein aggregates, including 
intracellular neurofibrillary tangles (formed of 
hyperphosphorylated tau protein) and extracellular 
senile plaques (formed of fibrillary amyloid beta (Aβ) 
peptides) [1]. Accumulation of misfolded protein, in 
association with deficient immune response (chronic 
activation and disturbance of microglial clearance 
functions) [2], is the main cause of neuronal death and 
associated cognitive dysfunction seen in AD patients 
[3]. Current diagnostic methods, based on cognitive 
tests, fail to detect early AD onset, while imaging 
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modalities such as magnetic resonance imaging (MRI) 
can detect structural brain changes only at advanced 
stages of disease [4]. In recent years substantial 
resources have also been invested in the identification 
of biomarkers in cerebrospinal fluid (CSF), to identify 
a prodromal AD signature that could improve 
diagnosis [5]. There is therefore a clear need to 
develop non-invasive neuroimaging-based methods 
for precise and early detection of this disease. 
Accurate in vivo imaging of Aβ plaque 
deposition could be a fundamental step towards 
effective early diagnosis of AD, as well as an 
important tool for monitoring of therapy efficacy and 
disease progression. Over the last decade, several 
small organic Aβ-targeting compounds have been 
identified, including benzothiazoles, stilbenes [6] and 
thioflavin T derivatives, such as the Pittsburgh 
Compound B (PiB) [7]. Despite good blood-brain 
barrier (BBB)-crossing ability, high in vivo binding 
affinity towards Aβ and suitable properties for usage 
in positron emission tomography (PET), their clinical 
application is limited by short radioisotope lifetime, 
use of ionising radiation and low spatial resolution. In 
contrast to nuclear imaging modalities, MRI allows 
non-invasive imaging of brain structures with 
superior spatial resolution, avoiding patient exposure 
to ionising radiation and at a smaller cost. MRI 
resolution can be further enhanced by paramagnetic 
contrast agents, including gadolinium (Gd3+) chelates 
or iron oxide nanoparticles [8]. Given the high 
electronic spin and slow relaxation times, Gd3+ 
complexes are the most widely used MRI contrast 
materials [8]. Selenium-based nanoparticles have also 
been successfully tested for Aβ binding and 
disruption, although their in vivo activity has yet to be 
demonstrated [9, 10]. 
Aiming at developing metal-based multimodal 
imaging probes for detection of Aβ plaques, PiB 
derivatives have been synthesised by conjugation to 
1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid 
(DO3A) monoamide [11, 12], a non-ionic macrocyclic 
chelator that forms stable, neutral complexes with 
trivalent metal ions, including Gd3+ (for MRI) and 
Indium-111 (111In3+) (for single-photon emission 
computed tomography, SPECT). Moreover, the 
intrinsic fluorescence of the PiB moiety [13] could 
potentially allow for high-resolution optical 
microscopy tracing of the imaging probe. While ex 
vivo staining of human AD brain tissue showed that 
these derivatives selectively target Aβ plaques [11], 
their clinical application is limited by the reduced 
ability to cross the BBB [11, 12]. The BBB permeability 
of a compound is directly influenced by three main 
physico-chemical and physiological parameters: (i) 
lipophilicity, represented by the water/octanol 
partition coefficient (log Poct/water), (ii) molecular 
weight and (iii) plasma pharmacokinetics [14]. In 
previous studies, it was shown that the lipophilicity of 
the PiB derivatives Gd(L1) and Gd(L2) (log Poct/water = 
-0.15 and 0.03, respectively) [11, 12] is reduced 
compared to the highly lipophilic PiB (log Poct/water = 
1.23) and other compounds with optimal BBB 
permeation (log Poct/water ~2) [15]. Biodistribution 
experiments in healthy adult Swiss mice using an 
111In-labelled analogue of Gd(L1) have also revealed 
moderate BBB penetration (0.36 % of the injected dose 
per gram of tissue in the cortex at 2 min after injection) 
[11].  
To improve brain delivery, impermeable 
compounds could be conjugated to nanocarriers 
capable of translocating across the BBB - either per se 
or upon targeting to transporters expressed in the 
brain vasculature - and reaching the desired regions 
in the brain [16]. In this regard, carbon nanotubes 
(CNTs) display unique physico-chemical properties 
suitable for use in nanomedicine applications, 
including large surface area (allowing conjugation of 
therapeutic and imaging molecules), electrochemical 
stability and a high aspect ratio [17-19]. Further 
surface modification/functionalisation with hydroph-
ilic molecules, polymers or other biocompatible 
molecules can enhance CNT water dispersibility, 
reduce toxicity and improve target cell/tissue 
delivery [20-23]. Importantly, the ability of 
functionalised CNTs (f-CNTs) to cross biological 
barriers by energy-dependent (transcytosis) and 
independent (passive) mechanisms, as well as 
intrinsic optical and thermal properties, constitutes a 
major CNT advantage for brain-targeted theranostic 
applications, compared to other nanocarriers [24]. 
Previous in vitro and in vivo proof-of-concept studies 
from our group demonstrated that functionalised 
multi-walled carbon nanotubes (f-MWNTs) cross an 
intact BBB [25-27]. Functional degradation, including 
loss of cylindrical structure, was also reported for 
stereotactically-administered f-MWNTs in mouse 
brain, most probably mediated by peroxidases and 
other degradative enzymes released by microglia [28]. 
Aiming at improving brain delivery of optimised 
PiB derivatives, in this study two different complexes 
– Gd(L2) and Gd(L3) (Fig. 1) – were non-covalently 
conjugated to f-MWNTs. MWNT characterisation was 
performed using thermogravimetric analysis (TGA) 
and Kaiser test, while conjugation was evaluated 
using inductively coupled plasma mass 
spectrometry (ICP-MS) and fluorimetry. Finally, the 
ligands L2/L3 were conjugated to f-MWNTs and 
radiolabelled with 111In, thus allowing quantification 
of in vivo biodistribution and brain uptake by 
SPECT/CT and γ-scintigraphy. 
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Figure 1. Structure of ligands.  
 
 
Experimental Section 
Reagents and solutions  
Pristine MWNTs (NC3100, Batch #120710, > 95% 
wt. purity, average dimensions of 1.5µm (length) and 
9.5 nm (diameter)), were purchased from Nanocyl SA 
(Sambreville, Belgium). Chemicals (listed in 
Supplementary Materials) were purchased from 
Fisher Scientific, Sigma-Aldrich, Alfa Aesar, TCI 
Europe and CheMatech, and were used without 
further purification. Analytical grade solvents were 
used and were not purified further unless specified. 
Isopore hydrophilic and hydrophobic membrane 
filters (0.2 µm pore size) were purchased from Merck 
Millipore (Watford, UK). The radioactive probe 
111InCl3 as an aqueous solution in 0.5 M HCl was 
purchased from Mallinckrodt Pharmaceuticals (The 
Netherlands) which is used directly without further 
purification. Instant thin layer chromatography paper 
impregnated with silica gel (iTLC-SG) was obtained 
from Agilent Technologies (UK). Fetal bovine serum 
was purchased from First Link Ltd (UK). All reagents 
and analytical grade solvents were used without 
further purification, unless specified. Other materials 
and equipment used for chemical synthesis are listed 
in Supplementary Material. 
Synthesis of Gd(L2) and Gd(L3) 
Gd(L3) was synthesised as shown in Scheme 1. 
The synthesis of Gd(L2) has been previously reported 
[12]. For the synthesis of Gd(L3), reactions were 
monitored by thin-layer chromatography (TLC) on 
Kieselgel 60 F254 (Merck) on an aluminium support, 
with detection by examination under UV light (254 
nm), by spraying with ninhydrin, and by coloration of 
the complex with Dragendorff solutions. Polar affinity 
chromatography was performed with silica gel 
(SigmaAldrich). 1H and 13C NMR spectra were recor-
ded on a Bruker Avance Spectrometer using a 5mm 
BBFO probe at 599.903 and 150.860 MHz for 1 H and 
13C, respectively. High Resolution Mass spectrometry 
(HRMS) was performed at the Centre de Biophysique 
Moléculaire du CNRS in Orléans, France. 
4-(6-methoxybenzo[d]thiazol-2-yl)-N,N-dimethylanili
ne: 2 
In a round flask, 
4-(6-methoxybenzo 
[d]thiazol-2-yl)aniline 1 (500mg, 
1.95 mmol) and paraformaldehyde 
(600mg, 20 mmol) were dissolved 
in 50ml of acetic acid. After 1h at 
room temperature, sodium 
cyanoborohydride (400mg, 6.36 
mmol) was added and the solution 
was mixed overnight. The reaction 
was neutralised by adding 
ammonium hydroxide. A 
yellowish precipitate was formed, 
collected and washed with water 
to give, without further 
purifications, 538mg (97%) of 
compound 2.  
1H NMR (CDCl3, 298K, 
599.902 MHz): 3.05 (s, 6H, 
N-(CH3)2); 3.88 (s, 3H, -OCH3); 
6.74 (d, 3J= 8.9Hz, 2Har); 7.03 (dd, 
3J= 8.9Hz, 4J= 2.5Hz, 1Har); 7.32 (d, 
 
 
 
Scheme 1. Synthesis of Gd(L3). The reagents and conditions were as follows: a) paraformaldehyde, NaCNBH3, 
AcOH, RT, 12h, 97%; b) BBr3, CH2Cl2, 0°C, 1h, 99%; c) N-(6-Bromohexyl)phthalimide, K2CO3, Acetone, reflux, 72h, 
86%; d) NH2NH2, reflux, 2h, 99%; e) Chloroacetyl Chloride, NEt3, THF, 0°C, 3h, 83%; f) DO3A-tBu, K2CO3, CH3CN, 
reflux, 16h, 76%; g) TFA, CH2Cl2, RT, 3h, 82%; h) GdCl3, pH 5,5, 2h. 
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4J= 2.5Hz, 1Har); 7.86 (d, 3J= 8.9Hz, 1Har); 7.90 (d, 3J= 
8.9Hz, 2Har) 
13C NMR (CDCl3, 298 K, 150.86 MHz): 42.4 (2C, 
-N-(CH3)2); 56.0 (1C, -OCH3); 104.6 (1Car); 112.0 (2Car); 
115.1 (1Car); 121.8 (1Car); 123.0 (1Car); 128.7 (2 Car); 
136.0 (1Car); 152.1 (1Car); 157.3 (1Car); 166.7 (1Car) 
2-(4-(dimethylamino)phenyl)benzo[d]thiazol-6-ol: 3 
Compound 2 (500 mg, 1.76 mmol) was dissolved 
in 12ml of dichloromethane at 0°C and 4ml of boron 
tribromine 1M were added dropwise. The solution 
was mixed for 3h and neutralised by adding a 
solution of sodium hydroxide 1N and the extraction 
was made with ethyl acetate (3X 30ml). The organic 
fraction was collected, dried over magnesium sulfate 
and evaporated to give, without further purifications, 
471mg (99%) of product 3. 
1H NMR (DMSO-d6, 298K, 599.902 MHz): 3.07 (s, 
6H, -N-(CH3)2); 6.86 (d, 3J= 9.0Hz, 2Har); 6.98 (dd, 3J= 
8.7Hz, 4J= 2.4Hz, 1Har); 7.39 (d, 4J= 2.4Hz, 1Har); 7.78 
(d, 3J= 8.7Hz, 1Har); 7.86 (d, 3J= 9.0Hz, 2Har), 9.71 (1H, 
OH) 
2-(6-((2-(4-(dimethylamino)phenyl)benzo[d]thiazol-6-
yl)oxy)hexyl)isoindoline-1,3-dione: 4 
To a solution of N-(6-Bromohexyl)phthalimide 
(860mg, 2.77mmol) in 60ml of acetone were added 1g 
of potassium carbonate and a solution of compound 3 
(450mg, 1,66mmol) in 10ml of acetone. The mixture 
was refluxed 3 days. After cooling down to room 
temperature, the solid was filtered off and the solvent 
was evaporated. Crude product was dissolved in 5ml 
of dichloromethane and petroleum ether was added 
until precipitation. The white solid was isolated to 
give 715mg (86%) of compound 4. 
1H NMR (CDCl3, 298K, 599.902 MHz): 1.44 (m, 
2H, -CH2-CH2-CH2-); 1.54 (m, 2H, -CH2-CH2-CH2-); 
1.73 (m, 2H, -CH2-CH2-CH2-); 1.82 (m, 2H, 
-CH2-CH2-CH2-); 3.05 (s, 6H, -N-(CH3)2); 3.71 (t, 3J= 
7.2Hz, 2H, -CH2-CH2-NPht); 4.00 (t, 3J= 6.4Hz, 2H, 
-CH2O-); 6.74 (d, 3J= 8.9Hz, 2Har); 7.03 (dd, 3J= 8.9Hz, 
4J= 2.4Hz, 1Har); 7.28 (d, 4J= 2.4Hz, 1Har); 7.70 (m, 
2HPht); 7.85(m, 1Har, 2HPht); 7,90 (d, 3J= 8.9Hz, 2Har). 
13C NMR (CDCl3, 298 K, 150.86 MHz): 25.7(1C, 
-CH2-CH2-CH2-); 26.6 (1C, -CH2-CH2-CH2-); 28.5 (1C, 
-CH2-CH2-CH2-); 29.2 (1C, -CH2-CH2-CH2-); 37.9 (1C, 
-CH2-CH2-NPht); 40.1 (2C, -N-(CH3)2); 68.4 (1C, 
-OCH2-); 105.1 (1Car); 111.7 (2Car); 115.3 (1Car); 121.6 
(1Car); 122.7 (1Car); 123.1 (2CPht); 128.5 (2Car); 132.1 
(2CPht); 133.8 (2CPht); 135.8 (1Car); 148.8 (1Car); 151.8 
(1Car); 156.5 (1Car); 166.2 (1Car); 168.4 (2C, COPht) 
 HRMS (ESI): m/z for C29H29N3O3S, calculated 
499.1930; found 500.2005 [M+H]+  
4-(6-((6-aminohexyl)oxy)benzo[d]thiazol-2-yl)-N,N-d
imethylaniline: 5 
Compound 4 (700mg, 1.40mmol) was refluxed 
2h in 15 ml of hydrazine hydrate. After cooling down, 
product was extracted with dichloromethane (3 x 
30ml) and the organic fraction was washed twice with 
10 ml of brine. The organic phase was dried over 
magnesium sulphate and evaporated to afford to 
512mg (99%) of compound 5 as a yellow oil. 
1H NMR (CDCl3, 298K, 599.902 MHz): 1.42 (m, 
4H, CH2-CH2-CH2); 1.48 (m, 2H, -CH2-CH2-CH2-); 1.83 
(m, 2H, -CH2-CH2-CH2-); 2.72 (t, 3J= 6.4Hz, 2H, 
-CH2-CH2-NH2); 3.05 (s, 6H, -N-(CH3)2); 4.02 (t, 2H, 3J= 
6.4Hz, -CH2O-); 6.74 (d, 3J= 8.9Hz, 2Har); 7.02 (dd, 3J= 
8.9Hz, 4J= 2.4Hz, 1Har); 7.30 (d, 4J= 2.4Hz, 1Har); 7.84 
(d, 1H, Har); 7,90 (d, 3J= 8.9Hz, 2Har) 
13C NMR (CDCl3, 298 K, 150.860 MHz): 26.0 (1C, 
-CH2-CH2-CH2-); 26.7 (1C, -CH2-CH2-CH2-); 29.3 (1C, 
-CH2-CH2-CH2-); 33.8 (1C, -CH2-CH2-CH2-); 40.2 (2C, 
-N-(CH3)2); 42.2 (1C, -CH2-NH2); 68.5 (1C, -OCH2-); 
105.1 (1Car); 111.7 (2Car); 115.4 (1Car); 121.7 (1Car); 122.7 
(1Car); 128.5 (2Car); 135.8 (1Car); 148.9 (1Car); 151.9 
(1Car); 156.6 (1Car); 166.4 (1Car) 
HRMS (ESI): m/z for C21H27N3OS, calculated 
369.1875; found 370.1946 [M+H]+ and 371.2032 
[M+2H]2+ 
2-chloro-N-(6-((2-(4-(dimethylamino)phenyl)benzo[d
]thiazol-6-yl)oxy)hexyl)acetamide: 6 
To a solution of compound 5 (500mg, 1.35mmol) 
and triethylamine (565µl, 4.06mmol) in 15ml of dry 
THF at 0°C, was added dropwise a solution of 
chloroacetyl chloride (650µl, 4.06mmol) in 5 ml of dry 
THF. The mixture was stirred 3H and 60 ml of water 
was added. The solution was stored at 4°C overnight. 
Yellowish crystals were filtered off to give 499mg 
(83%) of compound 6. 
1H NMR (CDCl3, 298K, 599.902 MHz): 1.42 (m, 
4H, -CH2-CH2-CH2-); 1.48 (m, 2H, -CH2-CH2-CH2-); 
1.83 (m, 2H, -CH2-CH2-CH2-); 3.05 (s, 6H, -N-(CH3)2); 
3.35 (dt, 3J= 6.1Hz, 3J= 7.2Hz, 2H, -CH2-CH2-NHCO-); 
4.02 (t, 3J= 6.4Hz, 2H, -CH2O-); 4.05 (s, 2H, -CH2-Cl); 
6.59 (bs, 1H, -NHCO); 6.74 (d, 3J= 8.9Hz, 2Har); 7.02 
(dd, 3J= 8.9Hz, 4J= 2.4Hz, 1Har); 7.30 (d, 4J= 2.4Hz, 
1Har); 7.86 (d, 1H, Har); 7,90 (d, 3J= 8.9Hz, 2Har) 
13C NMR (CDCl3, 298 K, 150.860 MHz): 25.8 (1C, 
-CH2-CH2-CH2-); 26.6 (1C, -CH2-CH2-CH2-); 29.2 (1C, 
-CH2-CH2-CH2-); 29.3 (1C, -CH2-CH2-CH2-); 39.8 (1C, 
-CH2-NH2); 40.2 (2C, -N-(CH3)2); 42.7 (1C, -CH2-Cl); 
68.4 (1C, -OCH2-); 105.1 (1Car); 111.8 (2Car); 115.4 
(1Car); 122.6 (1Car); 125.5 (1Car); 128.6 (2Car); 135.8 
(1Car); 148.9 (1Car); 151.9 (1Car); 156.6(1Car); 165.8 
(1CO); 166.4 (1Car) 
HRMS (ESI): m/z for C23H28ClN3O2S, calculated 
445.1591; found 446.1663 [M+H]+  
Nanotheranostics 2018, Vol. 2 
 
http://www.ntno.org 
172 
2,2',2''-(10-(2-((6-((2-(4-(dimethylamino)phenyl)benzo
[d]thiazol-6-yl)oxy)hexyl)amino)-2-oxoethyl)-1,4,7,10
-tetraazacyclododecane-1,4,7-triyl)triacetic acid: 7 
To a solution of DO3A-tBu (300mg, 0.58mmol) 
and potassium carbonate (226 mg, 2 mmol) in 20 mL 
of dry acetonitrile was added a solution of 6 (310mg, 
0.7 mmol) in 15 mL of dry acetonitrile. The reaction 
mixture was stirred for 16 h at 90°C. After cooling, the 
solid was filtered off and the solvent was evaporated. 
The crude product was purified by flash chromatogr-
aphy (eluent: ethyl acetate/methanol 95/5) and 
407mg (76%) of product 7 were isolated as a yellow 
oil. 
1H NMR (CDCl3, 298K, 599.902 MHz): 1.40 (m, 
2H, -CH2-CH2-CH2-); 1.44 (s, 18H, -C(CH3)3); 1.45 (s, 
9H, -C(CH3)3); 1.48 (m, 2H, -CH2-CH2-CH2-); 1.61 (m, 
2H, -CH2-CH2-CH2-); 1.81 (m, 2H, -CH2-CH2-CH2-); 
2.25 (bs, 8H, -NCH2-CH2N-); 2.55 (bs, 4H, 
-NCH2-CH2N-); 2.85 (bs, 6H, -NCH2-CH2N-, 
-N-CH2-CONH-); 3.05 (s, 6H, -N-(CH3)2); 3.22 (dt, 3J= 
6.1Hz, 3J= 5.9Hz, 2H, -CH2-NHCO-); 3.39 (bs, 6H, 
-N-CH2-COOtBu); 3.99 (t, 3J= 6.4Hz, 2H, -CH2O-); 6.74 
(d, 3J= 8.9Hz, 2Har); 7.0 (dd, 3J= 8.9Hz, 4J= 2.4Hz, 1Har); 
7.31 (d, 4J= 2.4Hz, 1Har); 7.62 (t, 1H, NHCO); 7.84 (d, 
3J= 8.9Hz, Har); 7,90 (d, 2Har) 
13C NMR (CDCl3, 298 K, 150.860 MHz): 25.4 (1C, 
-CH2-CH2-CH2-); 26.4 (1C, -CH2-CH2-CH2-); 27.5 (3C, 
-C(CH3)3); 27.6 (6C, -C(CH3)3) ;28.8 (1C, 
-CH2-CH2-CH2-); 29.1 (1C, -CH2-CH2-CH2-); 38.7 (1C, 
-CH2-NHCO-); 39.9 (2C, -N-(CH3)2); 48.1 (4C, 
-NCH2-CH2N-); 52.0 (4C, -NCH2-CH2N-); 55.1 (2C, 
-N-CH2-COOtBu); 55.3 (1C, -N-CH2-COOtBu); 56.0 
(1C, -N-CH2-CONH-); 68.2 (1C, -OCH2-); 81.2 (2C, 
-C(CH3)3); 81.3 (1C, -C(CH3)3); 104.7 (1Car); 111.3 
(2Car); 115.1 (1Car); 120.9 (1Car); 122.1 (1Car); 128.1 
(2Car); 135.3 (1Car); 148.3 (1Car); 151.5 (1Car); 156.3 
(1Car); 165.9 (1Car); 171.0 (1C, -CONH-); 171.8 (2C, 
-COOtBu); 172.1 (1C, -COOtBu) 
HRMS (ESI): m/z for C49H77N7O8S calculated 
923.5554; found 924.5622 [M+H]+  
tri-tert-butyl 
2,2',2''-(10-(2-((6-((2-(4-(dimethylamino)phenyl)benzo
[d]thiazol-6-yl)oxy)hexyl)amino)-2-oxoethyl)-1,4,7,10
-tetraazacyclododecane-1,4,7-triyl)triacetate: L3 
To a solution of 7 (350mg, 0.38mmol) in 10 ml of 
dichloromethane was added 10ml of trifluoroacetic 
acid. The solution was stirred 3h at room temperature 
and the solvents were evaporated. The crude product 
was purified by flash chromatography on RPC18 
silica (eluent: H20/Methanol). 207mg (82%) of ligand 
L3 were isolated as a yellow powder. 
1H NMR (CDCl3, 298K, 599.902 MHz): 1.03 (bs, 
4H, -CH2-CH2-CH2-); 1.28 (bs, 4H, -CH2-CH2-CH2-); 
2.28 (bs, 6H, NCH2-CH2N, CH2-NHCO); 3.10-3.26 (bs, 
20H, NCH2-CH2N, CH2-NHCO, N-(CH3)2); 3.57 (bs, 
4H, N-CH2-COOH); 3.74 (bs, 4H, N-CH2-COOH, 
CH2O); 5.66 (bs, 2Har); 6.06 (bs, 1Har); 6.51 (bs, 1Har); 
6.95 (bs, 1H, Har); 7.33 (d, 1H, Har) 
HRMS (ESI): m/z for C37H53N7O8S calculated 
755.3676; found 757.3824 [M+2H]2+ and 758.3910 
[M+3H]3+ 
General procedure for the preparation of gadolinium 
(III) complexes:  
Gd(Lx) (x = 2,3) complexes were prepared by 
mixing aqueous solutions of GdCl3 and the ligand Lx 
in equimolar quantities and adjusting the pH to 5.5 
with aqueous NaOH (0.1 mM). The solutions were 
allowed to react for 2h at room temperature while the 
pH was continuously adjusted. The absence of free 
metal ion was checked in each sample using the 
xylenol orange test.  
Determination of Octanol-Water Partition 
Coefficient (log Poct/water) 
The partition coefficient of Gd(L3) was 
determined, following the method previously used, as 
the ratio of the concentration of the compound in 
octanol and concentration of the compound in the 
aqueous phase [11, 12]. Partition coefficient (P) = [solute] octanol phase [solute] aqueous phase 
The logarithm of the partition coefficient is 
referred to as the log P value. The ‘‘shake flask’’ 
method was used for the determination of log P. 
Water saturated with octanol and octanol saturated 
with water were used in the experiments. The 
benzothiazol ring absorbs strongly at approximately 
330 nm; therefore, the partition was quantified using 
UV spectrophotometry with a PerkinElmer Lambda 
19 UV–vis spectrophotometer. For each phase, the 
maximum wavelength was verified. A 1:1 volume 
ratio was used for the partitioning of the solution with 
Gd(L3). In a 2-mL Eppendorf tube, 0.5 mL of a 100 µM 
solution of Gd(L3) was added to 0.5 mL of the 
saturated phase of 1-octanol. Each sample was 
centrifuged for 30 min. Gd(L3) concentrations were 
determined in each phase using standard curves. 
Synthesis of functionalised MWNTs 
(f-MWNTs) 
The synthesis of f-MWNTs was performed in 
three sequential steps as described in Scheme 2 and 
previously reported [29].  
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Scheme 2. Synthesis of functionalised MWNTs (f-MWNTs). Pristine MWNTs were incubated under strong acidic conditions to produce oxidised MWNTs 
(ox-MWNTs). The carboxylic acid moieties of ox-MWNTs were reacted with a phthalimide-protected amine-terminated spacer via amide coupling reaction, in the presence of 
N-hydroxybenzotriazole (HOBt) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) (1:2:2:2 molar ratio). Cleavage of the protection group was 
performed under strong alkaline conditions using hydrazine, yielding carboxylate and amine-functionalised MWNTs (ox-MWNTs-NH3+). RT: room temperature; DMF: 
dimethylformamide. 
 
 (i) Oxidation: pristine MWNTs (100 mg) were 
suspended in 25 mL HNO3:H2SO4 (1:3), which was 
bath sonicated for 12 h (water was regularly changed 
to prevent overheating). Subsequently, the mixture 
was added to 500 mL of distilled water (dH2O) and 
vacuum filtered through a 0.2 μm hydrophilic 
membrane. The black solid (oxidised MWNTs, 
ox-MWNTs) was collected from the filter and purified 
by serial washing/filtration with 300 mL dH2O (1x), 
300 mL 5% NaOH (1x) and 200 mL methanol (1x).  
(ii) Amidation: ox-MWNTs (~34 mg, 0.076 
mmol) were suspended in 40 mL dimethylformamide 
(DMF) under bath sonication for 10 min and 
subsequently mixed with 1-ethyl-3-(3-dimethylamin-
opropyl)carbodiimide hydrochloride (EDC.HCl) 
(~29.1 mg, 0.152 mmol), N- hydroxybenzotriazole 
(HoBt) (~20.5 mg, 0.152 mmol) and phthalimide- 
protected amine-terminated spacer (~42.3 mg, 0.152 
mmol; synthesis described in Supplementary 
Material). The reaction was carried out under stirring 
at 60°C for 24 h, after which the ox-MWNTs were 
recovered by vacuum filtration through a 0.2 μm 
hydrophobic membrane. The collected black solid 
(amidated ox-MWNTs) was further purified by serial 
washing/filtration with 100 mL DMF (1x) and 100 mL 
methanol.  
(iii) Deprotection: amidated ox-MWNTs (32 mg) 
were suspended in 20 mL DMF under bath sonication 
for 10 min, 6 mL hydrazine monohydrate were then 
added to the reaction mixture and the suspension was 
continuously stirred for 24 h at room temperature 
(RT). The deprotected ox-MWNTs (ox-MWNTs-NH3+) 
were recovered by vacuum filtration through a 0.2μm 
hydrophobic filter and further purified via serial 
washing/filtration with 100 mL DMF (1x) and 100 mL 
methanol (final yield ~30 mg).  
Kaiser test 
Ninhydrin assay reagents (phenol/ethanol 42.55 
M, KCN/pyridine 0.02 M and ninhydrin/ethanol 0.28 
M) were prepared in the fume hood. Five hundred 
microliters of each reagent were added to 1 mg of 
ox-MWNTs or ox-MWNTs-NH3+, followed by bath 
sonication for 1 min and incubation at 100°C for 7 
min. Subsequently, 4.5 mL of ethanol:water (60:40) 
were added to the suspension, which was further 
centrifuged for 10 min at 1811 x g (~2000 rpm; 
Eppendorf 5810R, Fisher Scientific UK). The UV-vis 
absorbance of the supernatant was measured at 575 
nm against a standard curve of 2,2′-(Ethylenediox-
y)bis(ethylamine) (Fig. S1) in a Lambda 35 
spectrophotometer (Perkin Elmer, USA).  
Thermogravimetric (TGA) analysis 
Samples of pristine MWNTs, ox-MWNTs and 
ox-MWNTs-NH3+ (~1 mg) were loaded in platinum 
pans and the analysis was carried out on a TGA Q500 
(TA instruments, USA). Reaction was performed 
under constant nitrogen gas flow (90 mL/min) and 
consisted of temperature increase (from RT) and 
stabilisation at 100◦C for 20 min, followed by a 
controlled temperature increase (10◦C/min) up to 
1000 ◦C. Data analysis was performed using the 
Advantage software (TA instruments, USA). 
Conjugation of L2 and L3 or Gd(L2) and Gd(L3) 
to f-MWNTs 
Gd(L2) and Gd(L3) were conjugated to ox- 
MWNTs or ox-MWNTs-NH3+ at a molar ratio of 1:10 
(complex:f-MWNTs), as shown in Scheme 3. Since it is 
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difficult to calculate the number of benzene rings per 
f-MWNT, as well as the number of f-MWNTs in each 
sample, a ratio of 1 molecule of Gd(L2/3) to 10 benzene 
units was adopted. ox-MWNTs or ox-MWNTs-NH3+ 
were dispersed in 4 mL dH2O under bath sonication 
for 5 min and the ligands were added separately to 
each dispersion, which was briefly sonicated. The 
different dispersions (ox-MWNTs + Gd(L2), ox- 
MWNTs + Gd(L3), ox-MWNTs-NH3+ + Gd(L2) and 
ox-MWNTs-NH3+ + Gd(L3) were continuously stirred 
(300 rpm) for 48 h at RT. For recovery of the 
ligand:f-MWNT conjugates, the dispersions were 
vacuum filtered through 0.2 µm pore hydrophilic 
membranes, the black solid pellets (conjugates) were 
collected and purified via serial washing/filtration 
with 20 mL dH2O (3x), 20 mL methanol:dH2O (1:1) 
(2x) and 20 mL methanol (2x) (Scheme 3). Samples of 
the filtrate (supernatant containing unbound ligand) 
and washing fractions were collected for 
quantification via inductively coupled plasma mass 
spectrometry (ICP-MS) and fluorimetry. Samples of 
conjugates (Gd(L2):ox-MWNTs, Gd(L3):ox-MWNTs, 
Gd(L2):ox-MWNTs-NH3+ and Gd(L3):ox-MWNTs- 
NH3+) were collected for quantification of bound 
ligand via ICP-MS. The same protocol was followed 
for conjugation of Gd3+-free L2/3 to ox-MWNTs or 
ox-MWNTs-NH3+. 
Quantification of ligand loading by ICP-MS 
ICP-MS quantification of Gd3+ conjugated to 
f-MWNTs was performed as described previously for 
Fe3+ conjugated to CNTs [30]. Suitable dilutions of 
Gd3+ standards (Ricca Chemical, TX, USA) were 
prepared in 10% nitric acid to obtain a Gd3+ standard 
curve in the range of 10-3-103 parts per million (ppm) 
(1 ppm ~103 µg/L ~6.36 µmol/L; MW=157.25 g/mol). 
To remove any traces of metal, 15 mL non-sterile 
tubes were pre-treated with 10 mL HCl (0.1 M) at 50°C 
for 30 min and dried before usage. Samples of 
conjugates (Gd(L2):ox-MWNTs, Gd(L3):ox-MWNTs, 
Gd(L2):ox-MWNTs-NH3+, Gd(L3):ox-MWNTs-NH3+), 
filtrate and washes were digested by incubation with 
2 mL HNO3 (67%) for 24 h at 80°C. The resulting 
solutions were diluted with dH2O to reach a 
concentration within the calibration range (average 
final volume of 10 mL) and subsequently centrifuged 
at 4000 rpm for 30 min (Eppendorf 5810R, Fisher 
Scientific UK) to ensure the removal of f-MWNTs 
from the solution. The Gd3+ content in the samples 
was measured against a standard 
curve of Gd3+ (Fig. S2) using the 
NexION 350D ICP mass spectrometer 
(Perkin Elmer, USA) with Cetac ASX 
520 autosampler and Syngistix 
software. Sample flow was kept at 0.2 
mL/min, argon flow (main, aux, 
nebuliser) at 18, 1.2 and 1.0 L/min, 
and RF coil power was 1600 W. An 
average of 5 different replicates was 
performed per sample measurement 
(with 50 sweeps/replicate).  
Quantification of complex 
loading by fluorimetry 
The excitation and emission 
spectra of Gd(L2) and Gd(L3) were 
determined using the LS50B 
Luminescence Spectrophotometer 
(Perkin Elmer, USA) (Fig. S3A, B). 
For sample quantification, 100 µL 
were loaded onto a black 96-well 
Costar plate (Corning, USA) and the 
fluorescence intensity was measured 
against standard curves of Gd(L2) or 
Gd(L3) (Fig. S3C, D) with the 
FLUOstar Omega microplate reader 
(BMG Labtech, Aylesbury, UK), and a 
machine gain of 500. 
 
 
Scheme 3. Conjugation of Gd(L2) or Gd(L3) to f-MWNTs. Gd(L2) or Gd(L3) were conjugated to 
ox-MWNTs or ox-MWNTs-NH3+ by incubation under stirring for 48 h at RT. To remove the unbound complex, 
the conjugates (Gd(L2):ox-MWNTs, Gd(L3):ox-MWNTs, Gd(L2):ox-MWNTs-NH3+ and 
Gd(L3):ox-MWNTs-NH3+) were vacuum filtered through a hydrophilic membrane. The pellet recovered on the 
filter contains the bound complex, whereas the supernatant (filtrate) contains unbound complex. 
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Radiolabelling of L2/3 and L2/3:f-MWNTs 
conjugates with 111In 
Radiolabelling L2 with 111In has been reported 
previously [11]. In this work, radiolabelling was 
performed on L2/3:ox-MWNTs and L2/3:ox-MWNTs- 
NH3+ conjugates with the labelling approach modified 
accordingly. Dispersions of f-MWNTs (1 mg/ml, in 
H2O) were mixed with 111InCl3 buffered in ammonium 
acetate (pH 5.5). Solutions were incubated for 30 min 
at room temperature and were vortexed every 5 min 
for thorough mixing. Solutions of L2/3 (1 mg/ml in 
H2O) were also subjected to the same labelling 
procedures. The labelling efficiency was assessed by 
iTLC (mobile phase, 3.5% NH4+: methanol (1:1), pH 
11). The auto-radioactivity of each TLC strip was 
developed and counted quantitatively using a 
Cyclone phosphor detector (Packard Biosciences). 
EDTA solution (0.1 M, 1/20, v/v) was then added to 
the f-MWNTs mixture to chelate any excess unreacted 
111InCl3. Labelled 111In(L2/3):f-MWNTs dispersions 
were pelleted by centrifugation at 13,000 rpm for 30 
min while unreacted 111In remained in the 
supernatant. The pelleted 111In(L2/3):f-MWNTs were 
resuspended in 1X PBS at 1 mg/ml for injection. iTLC 
(mobile phase: 0.1 M ammonium acetate buffer 
containing 50 mM EDTA) was carried out after 
addition of EDTA and after centrifugation. For 
labelled 111In(L2/3), solutions were buffered with 10X 
PBS to become isotonic for injection without the 
addition of EDTA.  
The stability of radiolabelling was examined by 
incubating 111In(L2/3):f-MWNTs dispersions and 
111In(L2/3) solutions with an equal volume of PBS or 
FBS at 37 °C for 24 h. The solutions were subjected to 
iTLC analyses as described above.  
Different amounts of 111InCl3 were used for 
radiolabelling for different studies according to the 
labelling efficiency and radioactivity required. The 
radioactivity in each injection dose was ~10 MBq and 
~1 MBq for SPECT/CT imaging and γ-scintigraphy 
studies respectively. 
Animals 
In vivo experiments were conducted under the 
authority of project and personal licences granted by 
the UK Home Office and the UKCCCR Guidelines 
(1998). Female C57BL/6 mice aged 6–8 weeks were 
purchased from Charles River (UK) for all the 
experiments. Details about animal husbandry and 
welfare are provided in Supplementary Material. 
SPECT/CT 
The biodistribution of intravenously 
(i.v.)-injected 111In-labelled L2/3, L2/3:ox-MWNTs, and 
L2/3:ox-MWNTs-NH3+ was firstly examined by 3D 
whole body SPECT/CT imaging. Mice were injected 
via tail vein with 100 μg of labelled 111In(L2/3):f- 
MWNTs (1 mg/ml in PBS) or In(L2/3) alone (100 μg) 
under isoflurane anaesthesia. SPECT/CT scans were 
carried out on the same animal at multiple time 
points: immediately after injection, at 4 h and 24 h. 
Mice were placed in the prone position and SPECT 
scans were acquired over 24 projections (60 s per 
projection), using a 4-head scanner with 1.4 mm 
pinhole collimators, for a total acquisition time of 
30–40 min (Nano-SPECT/CT, USA) [27]. CT scans 
(45 kVP X-ray) were performed after each SPECT. All 
images were reconstructed by MEDISO software 
(Medical Imaging Systems), and SPECT and CT 
images were merged using the VivoQuantTM software 
(inviCRO, USA). 
γ-scintigraphy 
Quantitative organ uptake of i.v. injected 
111In-labelled L2/3 and L2/3:ox-MWNTs-NH3+ was 
assessed by γ-scintigraphy. Mice were injected via a 
tail vein with 111In(L2/3):ox-MWNTs-NH3+ (50 μg per 
mouse) or 111In(L2/3) (50 μg per mouse) under 
isoflurane anaesthesia. At 2, 5, 10 and 30 min after 
injection, blood samples were collected from the 
lateral tail vein and the mice were perfused with 
50 mL of heparinised saline solution (50 U/mL) 
through the left ventricle of the heart to wash out the 
111In-labelled compounds remaining in circulation or 
loosely attached to tissues. Major organs (including 
brain) were excised, weighed and the radioactivity 
was measured by gamma counting (LKB Wallac 1282 
Compugamma, PerkinElmer). Results (mean ± SD,  
n=3) are expressed as % of injected dose per gram of 
organ (% ID/ g of organ), unless otherwise stated. 
Capillary depletion 
Brain tissues were subjected to capillary 
depletion, i.e. separation of brain parenchyma from 
blood vessels (capillaries), as described previously 
[31]. Briefly, each brain was homogenised in a glass 
homogeniser containing 1 mL of ice-cold depletion 
buffer (10 mM HEPES in HBSS, pH 7.4) via 15 stokes 
of the pestle, followed by addition of 1.6 mL of 
depletion buffer containing 26% dextran (148 kDa) 
and repeated pestle homogenisation (3 strokes). The 
homogenates were centrifuged at 3220 x g (Eppendorf 
5810R, Fisher Scientific UK) for 15 min to separate 
parenchyma (supernatant) and capillaries (pellet), 
and the radioactivity was measured using gamma 
counting (LKB Wallac 1282 Compugamma, 
PerkinElmer). Results (mean ± SD, n=3) are expressed 
as % of injected dose per brain fraction (% ID/brain 
fraction) followed by the analysis of brain 
parenchyma to blood ratio. 
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Statistical analysis 
Data are presented as mean ± standard deviation 
(mean ± SD) of at least two different experiments, 
unless otherwise stated. Statistical analysis was 
performed on GraphPad Prism (GraphPad Software, 
CA, USA) using one-way ANOVA with Tukey’s 
multi-comparison test, unless otherwise stated. 
Results and discussion 
Synthesis and characterisation of Gd(L2), 
Gd(L3) and f-MWNTs  
The synthesis of the ligand L2 was previously 
reported and the synthetic pathway of L3 is outlined 
in Scheme 1. 4-(6-methoxybenzo[d]thiazol-2-yl)ani-
line 1 was prepared according to the procedures 
described in the literature [12]. Then, in a reductive 
amination reaction, the N-dimethylated derivative 2 
was obtained in very high yield, and the ether 
function was quantitatively cleaved with boron 
tribromide. The linker was then introduced by 
nucleophilic substitution between product 3 and 
N-(6-Bromohexyl)phthalimide and the removal of the 
phtalimide protecting group was performed with 
hydrazine hydrate, giving the corresponding amine 5, 
which was acylated with chloroacetyl chloride to 
afford the amide derivative 6. Protected compound 7 
was obtained by N-alkylation of tri-tert-butyl 
2,2',2''-(1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triac
etate (DO3A-tBu) with 6 under classical conditions in 
presence of a base, in acetonitrile. The acid-sensitive 
tert-butyl protecting groups were then removed with 
trifluoroacetic acid in dichloromethane to give the 
final ligand L3. The gadolinium complexes Gd(L2) and 
Gd(L3) were formed by adding the gadolinium salt at 
a controlled pH of 5,5. 
Since the conjugation (via adsorption) of ligands 
on MWNTs is dependent on the hydrophobicity of the 
probes, an increase in the log P values of the ligands 
could be beneficial. The ligand structures diverge on 
the spacer used for conjugation of the PiB derivative 
to Do3A, with amide or ether linkages being used in 
L2 and L3, respectively. The lipophilicity of L3/ Gd(L3) 
was also modulated by introducing two methyl 
groups on the amine function. Consequentially, the 
log P value of Gd(L3) shows a gain in lipophilicity 
(Log P = 0.63) compared to Gd(L2) (Log P = 0.03).  
Due to high hydrophobicity, pristine MWNTs 
are not easily dispersed in water. Moreover, the 
reduced diameter (~9.5 nm) of the MWNTs used in 
this study makes them prone to aggregation in 
aqueous solution [32]. For this reason, pristine 
MWNTs were initially oxidised by incubation (under 
sonication) with a mixture of sulphuric and nitric 
acid, to promote chemical exfoliation of the nanotube 
surface, addition of carboxylic (COOH) groups and, 
consequently, increasing water dispersibility and 
decreasing possible cell toxicity (Scheme 2). 
Functionalisation via oxidation has also been shown to 
enhance renal clearance and decrease reticuloendo-
thelial system accumulation [33]. The presence of 
carboxylate groups on the side-wall defects and tips 
of MWNTs also allows for introduction of additional 
functional groups [34]. Indeed, oxidised MWNTs 
(ox-MWNTs) were further functionalised via 
amidation reaction between COOH groups and a 
phthalimide-protected amine-terminated spacer 
(Scheme 2). Deprotection of the spacer was achieved 
by alkaline treatment, yielding ox-MWNTs with 
positively charged primary amine groups 
(ox-MWNTs-NH3+). The introduction of functional 
groups to the surface of pristine MWNTs was 
confirmed by TGA and Kaiser test. TGA allows 
accurate determination of MWNT functionalisation 
by assessing sample weight loss upon exposure to 
gradually increasing temperature (under inert 
atmosphere). The weight loss is directly related to the 
introduction of functional groups onto the side-walls 
of f-MWNTs. As shown in Fig. 2A, pristine MWNTs 
exhibit high thermal stability (i.e. residual weight 
loss) up to 700 °C, after which the benzene backbone 
starts to decompose. In comparison, substantial 
weight loss was detected for ox-MWNTs at 600 °C 
(~13.5%), indicating the thermal degradation of 
carboxylic groups. Additional weight loss was 
detected for the amidated ox-MWNTs at 600 °C 
(~9.2%, total mass loss = 22.7%), which confirms the 
degradation of amine groups on the surface of 
ox-MWNTs-NH3+.  
Surface functionalisation with amine groups was 
further confirmed using Kaiser test, a semi- 
quantitative colorimetric test based on the reaction of 
the ninhydrin reagent with free primary amine 
groups [35]. Fig. 2B shows a representative assay 
image, with the development of pink colour (i.e. 
presence of amine groups) for ox-MWNTs-NH3+, 
while no colour development is seen for ox-MWNTs 
(do not contain primary amine groups). An average of 
203 µmol of amine groups per gram of 
ox-MWNTs-NH3+ was obtained using the Kaiser test, 
a value considerably smaller than that determined by 
TGA (687 µmol NH2/g of ox-MWNTs-NH3+) (Table 
1). This difference is most probably caused by residual 
aggregation of ox-MWNTs-NH3+, which limits the 
number of amine groups available to react with the 
ninhydrin reagent [25, 35]. The amine content of 
ox-MWNTs-NH3+ used this study is nevertheless 
similar to that reported in previous studies from our 
group, with values ranging from 100 to 530 µmol of 
amine groups per gram of MWNTs generated by 
amidation reaction [25, 26, 29, 34].  
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Figure 2. Characterisation of f-MWNT functionalization using TGA and Kaiser test. (A) Thermal decomposition of pristine, oxidised (ox-MWNTs) or oxidised and 
aminated carbon nanotubes (ox-MWNTs-NH3+) under increasing temperature. Functional groups present on f-MWNTs, such as COOH and NH3+, are degraded at 
temperatures below 600°C (which is reflected by the increasing weight loss), whereas no significant degradation (i.e. residual weight loss) is seen with pristine MWNTs. (B) 
Representative image of the colorimetric detection of free primary amine groups on the surface of MWNTs (via Kaiser test). No color development is seen with ox-MWNTs (1 
mg) (left), whereas development of pink coloration is seen with ox-MWNTs-NH3+ (1 mg) (right). 
 
Table 1. Quantitative characterisation of MWNT functional-
isation by TGA and Kaiser test. 
f-MWNTs μmol of functional group per gram of 
MWNTs  
 
  TGA (a) Kaiser test (b)  
ox-MWNTs 2446 ± 770 - COOH 
ox-MWNT-NH3+ 682 ± 10 203 ± 21 NH2 
(a) Measured using TGA. 
(b) Measured by Kaiser test. 
 
 
Taking into consideration the extent of MWNT 
oxidation determined by TGA (2446 ± 770 µmol 
COOH/ g of ox-MWNTs), the data indicates that ~1/3 
of the carboxylate groups were functionalised with 
the amine-terminated linker. The size of the f-MWNTs 
has been studied previously, with the mean diameter 
of ox-MWNTs measured between 6 and 12 nm and 
the mean length between 370 and 570 nm, by 
transmission electron microscopy and subsequent 
image analysis with Image J [26, 33]. The amidation 
reaction and conjugation of ligands are not expected 
to affect nanotube length, due to absence of oxisiding 
acid in this step. Similar to what has been observed in 
our previous studies [25, 26, 33, 34], good water 
dispersibility was obtained for both ox-MWNTs and 
ox-MWNTs-NH3+ (data not shown). 
Conjugation of Gd(L2) or Gd(L3) to f-MWNTs 
Since Gd(L2)/Gd(L3) contain aromatic rings in 
their structure, the conjugation to ox-MWNTs or 
ox-MWNTs-NH3+ – by simple mixing under stirring – 
relied on hydrophobic interactions between the 
ligands and MWNTs. Conjugation was assessed by 
two complementary techniques, ICP-MS and 
fluorimetry, upon separation of MWNT-bound and 
unbound ligand fractions by vacuum filtration 
(Scheme 3). ICP-MS was used to quantify Gd3+ in 
MWNT-bound and unbound fractions, providing an 
indirect measurement of Gd(L2/3) conjugated to the 
MWNTs. Taking advantage of the intrinsic 
fluorescence of L2/3, fluorimetry was used to quantify 
the ligands in the unbound fraction, while 
quantification of the MWNT-bound fraction by this 
technique is hampered by the fluorescence-quenching 
properties of the MWNTs. 
 
Table 2. Quantification of ligand loading onto f-MWNTS by 
ICP-MS and fluorimetry. 
f-MWNTs μmol of ligand per gram of f-MWNTs (a) 
  Gd(L2)  Gd(L3) 
 ICP-MS Fluorimetry (c) ICP-MS (b) Fluorimetry 
 ox-MWNTs 389 ± 438 542 ± 42  222 ± 70  203 ± 2 
ox-MWNT-NH3+ 60 ± 14 577 ± 8  105 ± 33  51 ± 29 
a) Values are presented as mean ± SD. 
b) Measured by ICP-MS. 
c) Obtained by subtracting the unbound fraction (measured by fluorimetry) from 
the total ligand in reaction. 
 
 
As shown in Table 2, higher levels of Gd(L2) and 
Gd(L3) were found conjugated to ox-MWNTs by 
ICP-MS (389 ± 438 and 222 ± 70 μmol of complex/g of 
f-MWNTs, respectively) compared to ox-MWNT- 
NH3+ (60 ± 14 and 105 ± 33 μmol of complex/g of 
f-MWNTs). Similarly, significantly higher levels of 
Gd(L2/3) were found conjugated to ox-MWNTs when 
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loading was measured by fluorimetry (p=0.0071, 
two-way ANOVA). The favourable ligand loading 
onto ox-MWNTs is probably related to the steric 
hindrance generated by the amine-terminated spacer, 
which partly blocks the interaction between aromatic 
rings of ligands and f-MWNTs. A trend towards more 
efficient conjugation of Gd(L2) was also detected by 
both ICP-MS and fluorimetry (389 ± 438 and 542 ± 42 
µmol of ligand/g of f-MWNTs, respectively), when 
compared to Gd(L3) (222 ± 70 and 203 ± 2 µmol of 
ligand/g of f-MWNTs) (p=0.54 for ICP-MS, p=0.0069 
for fluorimetry; two-way ANOVA). This observation 
could possibly be justified by the difference in 
hydrophobicity of Gd(L2) and Gd(L3) (log P = 0.03 and 
0.63, respectively). 
Radiolabelling of L2/3 and L2/3:f-MWNTs 
conjugates with 111In 
Since the PiB-DO3A derivatives have high 
affinity for both gadolinium(III) and indium(III), 
(L2/3):f-MWNTs conjugates prepared without Gd3+ 
were radiolabelled with 111In3+, aiming at assessing 
the in vivo biodistribution and brain uptake of the 
constructs by SPECT/CT imaging and γ-scintigraphy 
with high sensitivity. Although indirect tracking of 
the f-CNT has been carried out in this study, it is 
worth reporting that label-free detection of f-CNTs in 
vivo has been previously reported by our group. 
Taking advantage of the optical properties of CNTs, 
we used Raman and multiphoton luminescence to 
confirm the direct presence of systemically-administ-
ered f-MWNTs in mouse brain [27]. Furthermore, the 
presence of CNTs was confirmed by TEM in both 
whole brain and capillary fractions after intravenous 
injection in mice [27]. The results matched the indirect 
detection carried out by radiolabelling. We therefore 
adapted radiolabelling method to confirm the 
conjugation and track the organ biodistribution of L2 
and L3 ligands.  
The labelling efficiency was determined by iTLC 
analyses. Mobile phase consisting of 3.5 % 
NH4+:methanol (1:1) was used to test labelling 
efficiency of L2/3. As shown in Fig. 3A, labelled 
conjugates (111In(L2/3)) were detected at the solvent 
front (labelling efficiency > 60%). To test the labelling 
efficiency of (L2/3):f-MWNTs conjugates, a mobile 
buffer containing 50mM EDTA in 0.1 M acetate buffer 
was used, with an average labelling efficiency > 85% 
(spots at application point) being determined (Fig. 
3B). Removal of unconjugated 111In (in the form of 
[111In]EDTA) or [111In]L2/3) from the final sample was 
achieved by centrifugation. 
 
 
Figure 3. Labelling efficiency and stability studies of 111In-labelled L2/3 and their f-MWNTs conjugates. Radiolabelling of (A) L2/3 (B) L2/3:ox-MWNTs and 
L2/3:ox-MWNTs-NH3+ with 111In3+ was determined by iTLC analyses using 3.5 % NH4+: methanol (1:1, pH 11) (for L2/3) and 0.1 M ammonium acetate buffer containing 50 mM 
EDTA (pH 5.5) (for the conjugates) as the mobile phase. Dispersions of 111In(L2/3):f-MWNTs were treated with 0.1 M EDTA (1/20 v/v) prior TLC run to chelate unreacted 111In. 
(C) After centrifugation and re-dispersion in PBS, dispersions were incubated with or without FBS (1:1, v/v) at 37 °C for 24 h. The labelling stability was examined by iTLC (mobile 
phase: 0.1 M ammonium acetate buffer containing 50 mM EDTA). 
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Figure 4. Whole body SPECT/CT imaging of 111In-labelled L2/3 and L2/3:f-MWNTs conjugates following i.v. injection. C57BL/6 mice were injected via tail vein with 
~10 MBq of non-conjugated complexes 111In(L2/3) (100 µg) and their f-MWNTs conjugates 111In(L2/3):ox-MWNTs and 111In(L2/3):ox-MWNTs-NH3+ (200 µg). SPECT/CT imaging 
was carried out immediately after injection and at 4 and 24 h post injection. 
 
The labelling stability was assessed upon 
incubation in PBS or 50% FBS at 37 °C for 24 h. The 
iTLC results revealed that greater radiochemical 
stability was obtained for 111In(L2):f-MWNTs than 
111In(L3):f-MWNTs conjugate. The presence of serum 
had no influence on the stability (Fig. 3C).  
Whole body SPECT/CT imaging of 
111In-labelled conjugates following i.v. injection 
Whole body SPECT/CT imaging of 111In-labelled 
free ligands (L2/3) and (L2/3):f-MWNTs conjugates was 
performed to monitor the spatial distribution of the 
compounds upon i.v. administration in healthy mice. 
As shown in Fig. 4, marked differences in 
biodistribution were observed between 111In(L2/3) and 
the (L2/3):f-MWNTs conjugates. 
The SPECT/CT images at 30 min and 4 h post 
injection suggested that 111In(L2/3) underwent fast 
renal excretion as indicated by the strong signals 
detected in bladder and/or kidney. Biliary excretion 
was also observed evidenced by the intense signals in 
gallbladder and gut lumen within the first 4 h after 
injection. 
Unlike the free metal complexes, typical 
distribution patterns of 111In:f-MWNTs [26, 34] were 
obtained for the studied 111In(L2/3):f-MWNTs, 
indicating the successful conjugation of (L2/3) with 
f-MWNTs successful in chelating 111In. The 
biodistribution profiles were essentially established at 
the early time point for all the conjugates. 
111In(L2):ox-MWNTs showed accumulation in the 
order of lung>liver=spleen while 111In(L2):ox- 
MWNTs-NH3+ displayed comparable levels of uptake 
in these three organs. Reduction in lung uptake was 
observed for both 111In(L2):f-MWNTs over time. In 
contrast to 111In(L2):f-MWNTs, most of 111In(L3):f- 
MWNTs was detected in liver and, at a smaller extent, 
spleen (up to 24 h). Some signals were detected in the 
bladder/kidney (30 min) and in the gut lumen (4 h) 
suggesting dissociation of 111In(L2/3) from the 
conjugates.  
SPECT/CT images focusing on the brain at the 
early time point (30 min) are shown in Fig. 5. Signals 
of 111In(L2/3) were excluded from the brain cavity 
while some signals of 111In(L2/3):f-MWNTs can be seen 
inside and brain. 111In(L2/3):ox-MWNTs-NH3+ showed 
higher brain accumulation than 111In(L2/3):ox-MWNTs 
with the highest observed for 111In(L2):ox-MWNTs- 
NH3+.  
Quantitative assessments of organ uptake of 
111In(L2/3) and 111In(L2/3):ox-MWNTs-NH3+ 
following i.v. injection by γ-scintigraphy  
Quantitative organ biodistribution and brain 
uptake was performed by γ-scintigraphy for amine 
modified derivatives as they showed higher brain 
uptake than the carboxylated derivatives; 111In(L2/3) 
were used for comparison.  
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Figure 5. SPECT/CT images of 111In-labelled L2/3 and L2/3 :f-MWNTs conjugates in mouse brain following i.v. injection. C57BL/6 mice were i.v. injected with (A) 
111In(L2), 111In(L2):ox-MWNTs, and 111In(L2):ox-MWNTs-NH3+ and (B) 111In(L3), 111In(L3):ox-MWNTs, and 111In(L3):ox-MWNTs-NH3+, via a tail vein. SPECT/CT imaging was 
performed within 30 min post injection. 
 
As revealed in Fig. 6A, significantly higher levels 
of 111In(L2/3) were found in the blood 2 min after 
injection (~44.0-49.1 % ID) compared to MWNTs 
conjugates (~12.1-15.3 % ID) (p<0.001). The prolonged 
blood circulation time observed for 111In(L2/3) was 
possibly due to binding to serum proteins. The short 
blood circulation times detected for f-MWNTs 
conjugates agreed with our previous studies with 
values ranging from 6 to 14 % of ID at 2-5 min 
post-injection [25, 27].  
The analysis of the biodistribution profile of 
conjugates/complexes (Fig. 6B) revealed that 
111In(L2/3):ox-MWNTs-NH3+ accumulated primarily in 
the liver, spleen and lungs 30 min after injection, with 
differences between the two conjugates: while similar 
levels were detected in the liver (~23.5-30.9 %ID/g of 
tissue), preferential lung accumulation was found for 
111In(L2):ox-MWNTs-NH3+ (32.6 ± 5.8%ID/g of tissue) 
than 111In(L3):ox-MWNTs-NH3+ (12.7 ± 2.3 %ID/g of 
tissue) (p<0.01). On the contrary, higher spleen uptake 
was found for 111In(L3):ox-MWNTs-NH3+ (51.6 ± 12.9) 
than 111In(L2):ox-MWNTs-NH3+ (24.2 ± 10.3 %ID/g) 
(p<0.05). Uptake of f-MWNT in RES organs was 
previously reported in our studies [25-27, 34]. 
Agreeing with SPECT/CT data, 111In(L2/3) showed 
significantly higher levels in the kidneys (~51.1- 
74.9 %) compared to the conjugates (~6.1-16.3). 
The preferential accumulation of L2 and L3 
conjugates in the lung and spleen, respectively, could 
be due to difference in structure of possibly the final 
net charge of the conjugates. It has been shown in pre- 
clinical studies involving lipid-mediated delivery of 
siRNAs to dendritic cells that adjusting nanoparticle 
net charge to negative values can benefit spleen 
uptake, whereas positively-charged nanoparticles 
favour lung retention [36]. Although the 
physico-chemical, structural and biological properties 
of f-MWNTs and lipid nanoparticles are significantly 
different, this observation could help explain the 
differential uptake of 111In(L2/3):ox-MWNTs-NH3+ by 
lungs and spleen. Since L2 and L3 are probably 
neutrally charged at physiological pH, the 
determination of the net surface charge of 
111In(L2/3):ox-MWNTs-NH3+ complexes in the blood 
could is needed to help understand this observation.  
Importantly, previous histological studies from 
our group using organ samples from mice injected 
intravenously with ox-MWNTs-NH3+ showed no 
signs of tissue necrosis, fibrosis, or inflammation at 
different time points after administration (1h, 7 days, 
30 days) [33]. Moreover, in vivo degradation of CNTs 
has been demonstrated in different studies. Using 
TEM and Raman spectroscopy, our group found 
evidence of MWNT-NH3 + degradation in mouse 
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brain 14 days after stereotactic injection, with partial 
degradation following internalization and 
intracellular localization within microglia starting as 
early as 2 days after injection [28]. Studies by Kagan 
and colleagues using TEM, Raman spectroscopy and 
photoacoustic imaging have also shown 
peroxynitrite-induced macrophage-mediated degrad-
ation of SWNTs in lung tissue following pharyngeal 
administration in mice [37]. Nevertheless, further 
studies need to provide qualitative and quantitative 
data regarding the formation of by-products induced 
by CNT degradation, aiming at its clinical application. 
Fig. 6B revealed higher brain accumulation of 
111In(L2):ox-MWNTs-NH3+ (1.16 ± 0.23 %ID/g) than 
111In(L3):ox-MWNTs-NH3+ (0.22 ± 0.03 %ID/g 
(p<0.001) or 111In(L2/3) (~0.07-0.12 %ID/g) (p<0.001) at 
30 min post-injection. This value is superior to those 
reported for 111In-labelled L1 (0.36 and 0.5 %ID/g 
tissue in cortex and cerebellum at 30 min) [11], PiB 
[38] or Aβ-targeting ApoE-conjugated phosphatidic 
acid-encapsulating liposomes (a maximum of 0.3% 
ID/g of brain achieved at 24h after injection) [39]. 
Brain distribution profile of 111In(L2/3) and 
111In(L2/3):ox-MWNTs-NH3+ following i.v. 
injection by γ-scintigraphy  
To determine the amount of injected 
conjugates/ligands that reach the different brain 
tissues, endothelial cells (capillaries) and parenchyma 
were separated using capillary depletion (Fig. 7A). 
Higher levels of 111In(L2):ox-MWNTs-NH3+ were 
detected in both parenchyma and capillary fractions 
(~0.15 and 0.26 %ID/fraction, respectively) than 
111In(L3):ox-MWNTs-NH3+ (~0.04 and 0.09 %ID/ 
fraction, p<0.001 and 0.01). While a larger proportion 
of 111In(L2):ox-MWNTs-NH3+ was found in capillaries 
(~0.26 %ID), the difference to the parenchyma fraction 
was not statistically significant (~0.15 %ID; p>0.05 
using unpaired t-test with Welch’s correction). Values 
detected for 111In(L2/3) were all below 0.05 
%ID/fraction. 
A better measure for the extent of brain 
penetration – i.e. the translocation from blood to brain 
tissue across the BBB – is given by the brain 
parenchyma to blood ratio (P/B ratio) [40]. In this 
regard, the highest P/B ratio was obtained for 
111In(L2):ox-MWNTs-NH3+ (~0.074) compared to 
111In(L3):ox-MWNTs-NH3+ (~0.04, p<0.01) or to the 
residual values obtained for 111In(L2/3) (Fig. 7B). 
Overall, these results indicate that conjugation of 
L2 to ox-MWNTs-NH3+ significantly improved its 
brain accumulation while a small and non-significant 
improvement was obtained for L3. The whole-brain 
uptake values (~1.16 % ID/g of tissue) and P/B ratio 
(~0.074) obtained in this study were lower than those 
obtained in previous studies from our group (1.5 to 
3% ID/g of brain; 0.2 to 0.7 P/B ratio) [26, 39] and 
those of known CNS drugs (including morphine) [41] 
(P/B ratios > 0.5). They are however higher than those 
reported for other types of brain-targeting nanopart-
icles (0.3 to 0.5% ID/g of brain) [31, 42-44] and several 
clinical CNS drugs (~0.2% of administered dosage) 
[45-47]. Future conjugation to brain-targeting peptides 
(e.g. angiopep-2, a ligand of low-density lipoprotein 
receptor-related protein 1 (LPR-1)) may improve brain 
targeting even further [26]. 
 
 
Figure 6. Blood and organ biodistribution profiles of 111In-labelled L2 and L3, in its free form or conjugated to ox-MWNTs-NH3+, following systemic 
administration in healthy C57BL/6 mice. Mice were injected (via tail vein) with 111In-labelled L2/3 or 111In(L2/3):ox-MWNTs-NH3+ (50 μg, 0.5 MBq). Blood was sampled at 2, 
5, 10 and 30 min post-injection, followed by whole-body perfusion with heparinised saline. All major organs were immediately harvested and the radioactivity of (A) blood and 
(B) organs was measured by gamma counting. The Results are presented as (A) % injected dose per blood and (B) % injected dose per gram of tissue (inset: magnification of brain 
distribution). Statistical analysis of the results (mean ± SD, n = 3;) was performed using One-way ANOVA with Tukey’s posthoc test. (A) *** p<0.001 compared to animals 
injected with 111In(L2/3):ox-MWNTs-NH3+ and ## p<0.01 compared to animals injected with 111In(L2/3):ox-MWNTs-NH3+; (B) *** p<0.001 compared to animals injected with 
111In(L2/3) or 111In(L3):ox-MWNTs-NH3+; ## p<0.01 compared to animals injected with 111In(L2/3) or 111In(L3):ox-MWNTs-NH3+; + p<0.05, +++ p<0.001 compared to animals 
injected with 111In(L2):ox-MWNTs-NH3+ or L2/3, respectively; ^^ p<0.01, ^^^ p<0.001 compared to animals injected with 111In(L2):ox-MWNTs-NH3+ or 
111In(L3):ox-MWNTs-NH3+. 
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Figure 7. Brain distribution profile of 111In-labelled L2 and L3, in its free form or conjugated to ox-MWNTs-NH3+, following systemic administration in 
healthy C57BL/6 mice. Mice were injected (via tail vein) with 111In-labelled L2/3 or 111In(L2/3):ox-MWNTs-NH3+ (50 μg, 0.5 MBq). After measuring the radioactivity of the whole 
organs, brain tissues were processed to separate brain parenchyma from capillaries (via capillary depletion) and the radioactivity of each fraction was measured by gamma 
counting (A), with the data presented as % ID per total brain parenchyma or capillaries. (B) For brain parenchyma to blood ratio calculation, the weight of parenchyma was 
considered as the weight of the whole brain. Inset: magnification of brain parenchyma/blood ratio for L2 and L3. Statistical analysis of the results (mean ± SD, n = 3;) was 
performed using unpaired t-test with Welch’s correction. (A) *** p<0.001 compared to parenchyma of animals injected with 111In(L2/3) or 111In(L3):ox-MWNTs-NH3+ and ## 
p<0.01 compared to capillaries of animals injected with 111In(L2/3) or 111In(L3):ox-MWNTs-NH3+ (B) ** p<0.01 compared to animals injected with 111In(L3):ox-MWNTs-NH3+ and 
## p<0.01 compared to animals injected with 111In(L2/3). 
 
Conclusion 
This study provides evidence of the potential of 
functionalised MWNTs to be used as carriers for brain 
delivery of drugs/compounds that do not 
significantly cross the BBB, with possible clinical 
application in the diagnostic and treatment of 
neurological disorders. Future studies will aim at 
improving brain uptake of Gd(L2):MWNT conjugates 
via receptor-mediated transcytosis (by conjugation to 
angiopep1) and further testing the imaging and 
therapeutic ability in a relevant AD mouse model. 
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